Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Denmark (DKK) DKK
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Norway (NOK) NOK
Sweden (SEK) SEK
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Regulatory Status
- RUO
- Other Names
- B7-H4, B7H4T-cell costimulatory molecule, B7x, B7S1VCTN1,B7XPRO1291, FLJ22418, Immune costimulatory protein B7-H4;Protein B7S1, T cell costimulatory molecule B7x, V-set domaincontaining T cell activation inhibitor 1
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Biotinylated human B7-H4-Fc Chimera inhibits the anti-CD3 induced proliferation of activated human T cells in a dose-dependent manner. The ED50 for this effect is 0.3 - 3.0 µg/mL. -
Stability testing for Biotinylated human B7-H4-Fc Chimera: Biotinylated human B7-H4-Fc Chimera was aliquoted in PBS with 5% glycerol, pH 7.4 at 0.2 mg/mL and one aliquot was kept at 4°C (Control) for 7 days and another aliquot was frozen and thawed four times (4x Freeze/Thaw) over a period of one week. After this procedure, samples were tested for their ability to inhibit the anti-CD3 induced proliferation of activated human T cells in a dose dependent manner. The ED50 for this effect is 0.3 - 3.0 µg/mL.
| Cat # | Size | Price | Quantity Check Availability | Save | ||
|---|---|---|---|---|---|---|
| 718254 | 25 µg | 328€ | ||||
| 718256 | 100 µg | 712€ | ||||
B7-H4, also called v-set domain containing T cell activation inhibitor 1 (VTCN1) belongs to the type I transmembrane glycoprotein class. It is a constituent of the B7/CD28 superfamily, situated on chromosome 1p12/13.1 and encoded by the VTCN1 gene. The B7 family plays a pivotal role in modulating the immune response, preventing excessive immune activation and plays crucial role in T-signaling activation. B7-H4 emerged as a novel member of the B7 family of co-inhibitory molecules, functioning as an immune checkpoint modulator involved in regulating anti-inflammatory and immune responses. B7-H4 negatively regulates T-cell function. Structurally, B7-H4 comprises two immunoglobulin (Ig)-like domains and a large hydrophobic transmembrane domain followed by two intracellular amino acids. It shares variable levels of amino acid sequence identity with other B7 family members: B7-1 (12%), B7-2 (13%), PD-L1 (18%), PD-L2 (18%), and B7-H3 (24%). B7-H4 expresses on T-cells and antigen-presenting cells (APCs) and is induced by local cytokine production such as Il-6, IL-10, and hypoxia. The receptor for B7-H4, distinct from other members of the CD28 receptor family, is expressed on activated T cells, suggesting a potential role for B7-H4 in the regulation of T-cell activation and exhaustion. B7-H4 exhibits widespread expression across various malignancies and is inversely associated with patient prognosis and T cell infiltration within tumors. B7-H4 is another ‘checkpoint’, overexpression of which is indicative of poor prognosis and is linked with cancer progression.
Product DetailsProduct Details
- Source
- Human B7-H4-Fc Chimera, amino acids Phe29-Ala258 (Accession # Q7Z7D3), with a C-terminal Fc tag and Avi tag was expressed in CHO cells. Human B7-H4 was site-specifically biotinylated by BirA.
- Molecular Mass
- The 478 amino acid recombinant protein has a predicted molecular mass of approximately 53.21 kD. The DTT-reduced and non-reduced protein migrate at approximately 75 kD and 135 kD respectively in SDS-PAGE.
-
N-terminal
Sequence Analysis - The predicted N-terminal amino acid is Phe.
- Purity
- > 95%, as determined by Coomassie stained SDS-PAGE.
- Formulation
- 0.22 µm filtered protein solution is in PBS and 5% glycerol, pH 7.4
- Endotoxin Level
- Less than 0.1 EU per μg of protein as determined by the LAL method
- Concentration
- 25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at – 20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Activity
- Biotinylated human B7-H4-Fc Chimera inhibits the anti-CD3 induced proliferation of activated human T cells in a dose-dependent manner. The ED50 for this effect is 0.3 - 3.0 µg/mL.
- Application
-
Bioassay
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Monomer
- Distribution
-
Antigen presenting cells (dendritic cells, peritoneal macrophages, and splenic B cells), epithelium of normal tissues breast, pancreas, kidney and some tumor cells derived from mammary, ovary, and uterus
- Function
- B7-H4 inhibits T cell activation, proliferation, and cytokine production. B7- H4 is involved in regulating anti-inflammatory and immune responses.
- Interaction
- Activated T cells
- Bioactivity
- Biotinylated human B7-H4-Fc Chimera inhibits the anti-CD3 induced proliferation of activated human T cells in a dose-dependent manner. The ED50 for this effect is 0.3 - 3.0 µg/mL.
- Biology Area
- Costimulatory Molecules, Immunology
- Molecular Family
- Soluble Receptors
- Antigen References
-
- Sica GL, et al. 2003. Immunity. 18:849-61.
- Prasad DVR, et al. 2003. Trends in Pharmacological Sciences. 18:863-73.
- MacGregor HL, et al. 2019. Oncoimmunology. 8:e1665460.
- Li J, et al. 2018. Immunity. 48:773-786.
- Rodriguez-Garcia A, et al. 2017. Gynecologic Oncol. 145:426-35.
- Bregar A, et al. 2017. Gynecologic Oncol. 145:446-52.
- Zang X, et al. 2003. Proc Natl Acad Sci United States America. 100:10388-92.
- Kryczek I, et al. 2007. Cancer Res. 67:8900-5.
- Terry S, et al. 2020. Cancer Letters. 492:1-10.
- Piao L, et al. 2018. Hum. Pathol. 80:152-162.
- Wu L, et al. 2016. Cancer Immunol. Immunother. 9:1035-1045.
- Krambeck AE, et al. 2006. Proc Natl Acad Sci USA. 103:10391-10396.
- Yi KH, et al. 2009. Immunol Rev. 229:145-151.
- Gene ID
- 79679 View all products for this Gene ID
- UniProt
- View information about B7-H4 on UniProt.org
Follow Us